Behavioral Evaluations in Reproductive Safety Assessments

Abstract

Since 1974, behavioral tests have been a required component of developmental toxicity studies submitted to certain regulatory agencies. Behavioral test batteries are now widely used in industry to satisfy the international regulatory guidelines for safety assessments, but the choice of the most appropriate study design(s) in which to include these tests varies. We present data for 12 pharmaceutical agents tested in two or more of 28 Segment I, II, and/or III studies. The lowest observable effect levels (LOELs) in these studies indicate that behavioral effects can occur in each study design (regardless of exposure period), and no one design is necessarily more likely to produce a behavioral effect than any other. However, in determining the most appropriate study design in which to include behavioral testing, other considerations (e.g., pharmacokinetics, dosage levels tested) are important factors. A study design suggested by a group of international scientists proposing to harmonize guidelines for pharmaceutical safety testing appears to offer the optimal study design for testing behavioral effects. This study design combines the exposure periods of the existing Segment II and III studies, with specialized behavioral safety designs conducted on an as needed, case-by-case basis to identify dose-response relationships, critical periods, the full manifestation of effects. This proposed study design and general approach are identified as the most appropriate method of evaluating behavioral effects in regulatory safety assessments.

References

1. Christian, M.S. (1989). Behavioral-functional teratology, in: Current Issues in Toxicology, K. S. Khera , H. C. Grice , and D. J. Clegg (eds). New York: Springer-Verlag, pp. 41–58.

2. COMMITTEE ON THE SAFETY OF MEDICINES. (1974). Notes for Guidance on Reproduction Studies. London: Committee on the Safety of Medicines, Department of Health and Social Security.

3. JAPANESE PHARMACEUTICAL AFFAIRS BUREAU. (1984). Ministry of Health and Welfare. Notification No. 118. Information on the Guidelines of Toxicity Studies Required for Applications for Approval to Manufacture (Import) Drugs. (Part I), February 15, 1984.

4. U.S. ENVIRONMENTAL PROTECTION AGENCY. (1991). Pesticide Assessment Guidelines, Subdivision F, Hazard Evaluation: Human and Domestic Animals; Addendum 10; Neurotoxicity. Health Effects Division, Office of Pesticide Programs, March 1991.

5. Buelke-Sam, J. , and Kimmel, C.A. (1979). Development and standardization of screening methods for behavioral teratology. Teratology 20, 17–30.

6. Rodier, P.M. , Reynolds, S.S. , and Roberts, W.N. (1979). Behavioral consequences of interference with CNS development in the early fetal period. Teratology 19, 327–336.

7. Wilson, J.G. (1973). Environment and Birth Deficits. London: Academic Press, Inc.

8. U.S. FOOD AND DRUG ADMINISTRATION. (1966). Guidelines for Reproduction Studies for Safety Evaluation of Drugs for Human Use.

9. Bass, R., Baeder, C., Lehmann, H., Neubert, D., Palmer, A., and Sullivan, F. (1991). Draft Guideline on Detection of Toxicity to Reproduction for Medicinal Products (11 th Draft Issued June 1991). Proceedings from a meeting for harmonisation of existing guidelines, Centre of Medicines Research, London Guidelines, May 1991.

10.

10. Foss, J.A., Lochry, E.A., and Christian, M.S. (1991). A test battery for the evaluation of postnatal development of rats in safety assessments. Fund. Appl. Toxicol.

11.

11. Vorhees, C.V. (1986). Principles of behavioral teratology, in: Handbook of Behavioral Teratology, E. P. Riley and C. V. Vorhees (eds). New York: Plenum Press, pp. 23–48.

12.

12. Palmer, A.K. (1981). Regulatory requirements for reproductive toxicology: Theory and practice, in: Developmental Toxicology, C. A. Kimmel and J. Buelke-Sam (eds). New York: Raven Press, pp. 259–287.